Endnote x9 citation manager

This NMA is reported based on the Preferred Reporting Items for Systematic Reviews and Network Meta-Analysis statement (PRISMA) [39 (link)]. The NMA entailed a systematic search in CENTRAL, MEDLINE (via PubMed), Scopus, Web of Science, and Embase from the date of database inception to 7 October 2019, using free-text terms as follows: (((cystic fibrosis OR mucoviscidosis OR ‘lung disease’ OR ‘genetic disease’ OR cftr))) AND ((Pseudomonas OR P. aeruginosa)) AND Random*. We placed no restrictions such as year of publication or language on the search. Each document was downloaded into the EndNote X9 citation manager (Clarivate Analytics, Philadelphia, PA, USA) and title duplicates were eliminated by the citation manager and then manually detailed in Figure 3.

The EndNote X9 citation manager (Clarivate Analytics, Philadelphia, PA, United States) was employed to select the publications to be included. After the automatic and manual duplicate removal (E.G.), two investigators (I.L.H and E.G.) independently screened the retrieved records in two steps: first by title and abstract, and, subsequently, by full text. Cohen’s Kappa coefficient (κ) was calculated to evaluate the inter-rater agreement after each selection step. Disagreements were resolved by third party arbitration (G.B.K. and M.A.E.). Our inclusion criteria were based on the PRISMA statement and the guidelines of the Cochrane Collaboration^{33 ,34 (link)}.